No title
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used to treat type 2 diabetes mellitus and obesity. As their use expands, continued post-marketing safety monitoring is important, especially for uncommon but serious adverse events. Despite conflicting evidence regarding causality, pancreatitis, in particular, has remained a clinical and regulatory concern for GLP-1 drugs. Thi
